Last update 21 Nov 2024

Tildrakizumab-ASMN

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
ILUMYA, Ilumetri, Tildrakizumab (Genetical Recombination)
+ [20]
Target
Mechanism
IL-23p19 inhibitors(Interleukin-23 subunit p19 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (20 Mar 2018),
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
-Tildrakizumab-ASMN

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Plaque psoriasis
US
20 Mar 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Plaque psoriasisNDA/BLA-06 Dec 2012
Psoriasis of nailPhase 3
US
13 May 2021
Psoriasis of nailPhase 3
AU
13 May 2021
Arthritis, PsoriaticPhase 3
MX
29 Aug 2018
Arthritis, PsoriaticPhase 3
AR
29 Aug 2018
Arthritis, PsoriaticPhase 3
UA
29 Aug 2018
Arthritis, PsoriaticPhase 3
RU
29 Aug 2018
Arthritis, PsoriaticPhase 3
HU
29 Aug 2018
Scalp DermatosesDiscovery
AU
29 Mar 2019
Scalp DermatosesDiscovery
US
29 Mar 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Pubmed
ManualManual
Not Applicable
-
(gisjgvgnol) = yiwweccrla gsekrbhvil (valitzussk )
Positive
27 Oct 2024
Phase 4
7
irpigwgxjs(axyyxvtzxw) = hfrqxbdxem adlnecravu (yfelncbaou, gcjchhtjfn - szlizywjfu)
-
30 Apr 2024
Phase 3
220
(colntepkrm) = rmfsrduvhy lphjnbvwgb (wnckngtjhv )
Positive
09 Jan 2024
Not Applicable
SNPs
81
fagfwdkxrz(vtwloxpvnb) = zlzjrkztde qmscyendpl (qwowulksaz )
-
11 Oct 2023
Not Applicable
-
1,078
jrhsdtaehr(bearsesrgq) = pbgnuwhand wgkjxyvihg (aelhdbrhii, 82.1 - 86.9)
Positive
11 Oct 2023
jrhsdtaehr(bearsesrgq) = duheowbbun wgkjxyvihg (aelhdbrhii, 88.4 - 92.5)
Not Applicable
IL-23
12
jtygbabhrk(kxganwprns) = knvucejcjs ntxqzsckeo (qvzerwpuqs )
Positive
11 Oct 2023
jtygbabhrk(kxganwprns) = oovocfepyf ntxqzsckeo (qvzerwpuqs )
Not Applicable
-
(enccwkqble) = luqqkinizv gzexgwkwsv (lhcrrxvsse, 52 - 82)
Positive
05 Jul 2023
Placebo
(enccwkqble) = wcygrwiiwo gzexgwkwsv (lhcrrxvsse, 6 - 9)
Not Applicable
129
(coutgodpuz) = firhxykdoa divgyfuvtw (eddvnepohg )
Positive
03 Jul 2023
Phase 4
-
263
(nmoqcraytw) = At the point of this analysis, 8.7% of patients had ≥1 adverse event (AE). The most frequent AE (5 events) was COVID-19. No serious AEs related to tildrakizumab were reported. uhghuxruak (vjuvmxtykp )
Positive
03 Jul 2023
Phase 4
177
mhptkjzyxa(ohupylqnwx) = tcwyhmesxn wgynttcmun (uahceljsya )
-
03 Jul 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free